Stockreport
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
FDA Fast Track Designation granted for avutometinib in combination with adagrasib for the treatment of KRAS G12C-mutated metastatic non-small cell lung cancer FDA Fast Track Designation granted for avutometinib plus defactinib in combination with sotorasib for the treatment of KRAS G12C-mutated metastatic non-small cell lung cancer Initial safety and efficacy results from the RAMP 205 trial of avutometinib and defactinib in combination with current standard of care in first-line metastatic pancreatic cancer to be presented at the 2024 ASCO Annual Meeting BOSTON, May 09, 2024 BUSINESS WIRE )--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, we received FDA Orphan Drug Designation for avutometinib and defactinib combination in recurrent low-grade serous ovarian cance
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE[PR Newswire]
- The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. [Yahoo! Finance][Yahoo! Finance]
- SA Asks: Which weight-loss stocks should investors be watching? [Seeking Alpha][Seeking Alpha]
- Bristol's $250,000 Pill Slows Lung Cancer Growth by Seven Weeks [BNN Bloomberg (Canada)][BNN Bloomberg]
- Global Biosimilars and Follow-On Biologics Market Report 2024-2034 - Expanding the Portfolio of Biosimilars for Rare Diseases [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 6/3/24 - Form 8-K
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- AMGN's page on the SEC website
- More